Amphiregulin as a biomarker for monitoring lifethreatening acute graft-<i>versus</i>-host disease: secondary analysis of two prospective clinical trials

• Shernan G. Holtan,
• Najla El Jurdi,
• Armin Rashidi,
• Brian C. Betts,
• Connor Demorest,
• John P Galvin,
• Margaret L. MacMillan,
• Daniel J. Weisdorf,
• Angela Panoskaltsis-Mortari,
• Michael A. Pratta

Affiliations

Shernan G. Holtan

University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Najla El Jurdi

University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Armin Rashidi

University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN; Fred Hutchinson Cancer Center

Brian C. Betts

University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Connor Demorest

Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

John P Galvin

Incyte Corporation, Wilmington, DE

Margaret L. MacMillan

University of Minnesota, Pediatric Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Daniel J. Weisdorf

University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Angela Panoskaltsis-Mortari

University of Minnesota, Pediatric Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN

Michael A. Pratta

Incyte Corporation, Wilmington, DE